Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.

<h4>Goal</h4>Combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia may offer a promising strategy for treatment of dementia, which often has a multifactorial basis in the elderly. We investigated whether the phosphodiesterase III inhibitor cilostazol,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Masafumi Ihara, Madoka Nishino, Akihiko Taguchi, Yumi Yamamoto, Yorito Hattori, Satoshi Saito, Yukako Takahashi, Masahiro Tsuji, Yukiko Kasahara, Yu Takata, Masahiro Okada
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2014
Materias:
R
Q
Acceso en línea:https://doaj.org/article/c75ae3b23cee4040b68e76e235998f3d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c75ae3b23cee4040b68e76e235998f3d
record_format dspace
spelling oai:doaj.org-article:c75ae3b23cee4040b68e76e235998f3d2021-11-18T08:30:55ZCilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.1932-620310.1371/journal.pone.0089516https://doaj.org/article/c75ae3b23cee4040b68e76e235998f3d2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24586841/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Goal</h4>Combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia may offer a promising strategy for treatment of dementia, which often has a multifactorial basis in the elderly. We investigated whether the phosphodiesterase III inhibitor cilostazol, which is often used in the prevention of stroke and peripheral artery disease, may delay cognitive decline in the elderly receiving donepezil.<h4>Methods</h4>Medical records were retrospectively surveyed to identify patients who had received donepezil for more than one year and had undergone Mini-Mental State Examination (MMSE) at least at two time points. Those with an initial MMSE score of less than 27 points were subjected to analysis (n = 156), with a cut-point of 21/22 applied to assign them to mild (n = 70) and moderate/severe (n = 86) dementia. The change of total MMSE score per year was compared between patients who had received donepezil and those given both donepezil and cilostazol.<h4>Findings</h4>In patients with mild dementia who had received donepezil and cilostazol (n = 34; 77.2±6.8 years old), the annual change in MMSE score was -0.5±1.6 during an observational period of 28.6±11.7 months, with those receiving donepezil only (n = 36; 78.4±6.5 years old) scoring less (-2.2±4.1) during 30.4±12.8 months with a statistical intergroup difference (p = 0.022). Multivariate analysis showed that absence of cilostazol treatment was the only significant predictor of MMSE decline. A positive effect of cilostazol was found in three subscale scores of MMSE, orientation for time or place and delayed recall. By clear contrast, in patients with moderate/severe dementia, there were no intergroup differences in decrease of total or subscale MMSE scores between the two groups.<h4>Conclusions</h4>These results suggest potential for cilostazol treatment in the suppression of cognitive decline in patients receiving donepezil with mild dementia but not in those with moderate/severe dementia.Masafumi IharaMadoka NishinoAkihiko TaguchiYumi YamamotoYorito HattoriSatoshi SaitoYukako TakahashiMasahiro TsujiYukiko KasaharaYu TakataMasahiro OkadaPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 2, p e89516 (2014)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Masafumi Ihara
Madoka Nishino
Akihiko Taguchi
Yumi Yamamoto
Yorito Hattori
Satoshi Saito
Yukako Takahashi
Masahiro Tsuji
Yukiko Kasahara
Yu Takata
Masahiro Okada
Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
description <h4>Goal</h4>Combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia may offer a promising strategy for treatment of dementia, which often has a multifactorial basis in the elderly. We investigated whether the phosphodiesterase III inhibitor cilostazol, which is often used in the prevention of stroke and peripheral artery disease, may delay cognitive decline in the elderly receiving donepezil.<h4>Methods</h4>Medical records were retrospectively surveyed to identify patients who had received donepezil for more than one year and had undergone Mini-Mental State Examination (MMSE) at least at two time points. Those with an initial MMSE score of less than 27 points were subjected to analysis (n = 156), with a cut-point of 21/22 applied to assign them to mild (n = 70) and moderate/severe (n = 86) dementia. The change of total MMSE score per year was compared between patients who had received donepezil and those given both donepezil and cilostazol.<h4>Findings</h4>In patients with mild dementia who had received donepezil and cilostazol (n = 34; 77.2±6.8 years old), the annual change in MMSE score was -0.5±1.6 during an observational period of 28.6±11.7 months, with those receiving donepezil only (n = 36; 78.4±6.5 years old) scoring less (-2.2±4.1) during 30.4±12.8 months with a statistical intergroup difference (p = 0.022). Multivariate analysis showed that absence of cilostazol treatment was the only significant predictor of MMSE decline. A positive effect of cilostazol was found in three subscale scores of MMSE, orientation for time or place and delayed recall. By clear contrast, in patients with moderate/severe dementia, there were no intergroup differences in decrease of total or subscale MMSE scores between the two groups.<h4>Conclusions</h4>These results suggest potential for cilostazol treatment in the suppression of cognitive decline in patients receiving donepezil with mild dementia but not in those with moderate/severe dementia.
format article
author Masafumi Ihara
Madoka Nishino
Akihiko Taguchi
Yumi Yamamoto
Yorito Hattori
Satoshi Saito
Yukako Takahashi
Masahiro Tsuji
Yukiko Kasahara
Yu Takata
Masahiro Okada
author_facet Masafumi Ihara
Madoka Nishino
Akihiko Taguchi
Yumi Yamamoto
Yorito Hattori
Satoshi Saito
Yukako Takahashi
Masahiro Tsuji
Yukiko Kasahara
Yu Takata
Masahiro Okada
author_sort Masafumi Ihara
title Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
title_short Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
title_full Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
title_fullStr Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
title_full_unstemmed Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
title_sort cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
publisher Public Library of Science (PLoS)
publishDate 2014
url https://doaj.org/article/c75ae3b23cee4040b68e76e235998f3d
work_keys_str_mv AT masafumiihara cilostazoladdontherapyinpatientswithmilddementiareceivingdonepezilaretrospectivestudy
AT madokanishino cilostazoladdontherapyinpatientswithmilddementiareceivingdonepezilaretrospectivestudy
AT akihikotaguchi cilostazoladdontherapyinpatientswithmilddementiareceivingdonepezilaretrospectivestudy
AT yumiyamamoto cilostazoladdontherapyinpatientswithmilddementiareceivingdonepezilaretrospectivestudy
AT yoritohattori cilostazoladdontherapyinpatientswithmilddementiareceivingdonepezilaretrospectivestudy
AT satoshisaito cilostazoladdontherapyinpatientswithmilddementiareceivingdonepezilaretrospectivestudy
AT yukakotakahashi cilostazoladdontherapyinpatientswithmilddementiareceivingdonepezilaretrospectivestudy
AT masahirotsuji cilostazoladdontherapyinpatientswithmilddementiareceivingdonepezilaretrospectivestudy
AT yukikokasahara cilostazoladdontherapyinpatientswithmilddementiareceivingdonepezilaretrospectivestudy
AT yutakata cilostazoladdontherapyinpatientswithmilddementiareceivingdonepezilaretrospectivestudy
AT masahirookada cilostazoladdontherapyinpatientswithmilddementiareceivingdonepezilaretrospectivestudy
_version_ 1718421707959566336